ADCT ADC Therapeutics
- 4.780
- -0.190-3.82%
ADC Therapeutics News
ADC Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 424B3: Prospectus
ADC Therapeutics | 424B3: Prospectus
ADC Therapeutics | EFFECT: Others
ADC Therapeutics | EFFECT: Others
ADC Therapeutics | EFFECT: Others
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
ADC Therapeutics | ARS: Annual Report to Security Holders
ADC Therapeutics | 10-K: Annual report
ADC Therapeutics | 8-K: ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | 8-K: Current report
ADC Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Redmile Group, LLC(18.8%),Jeremy C. Green(18.8%), etc.
ADC Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Prosight Management, LP(8.0%),Prosight Partners, LLC(8.0%), etc.
ADC Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AstraZeneca PLC(4.88%),AstraZeneca UK Limited(4.88%)
ADC Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Redmile Group, LLC
ADC Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Redmile Group, LLC
Analysis
Price Target
No Data
